A carregar...

Molecular Monitoring in Chronic Myeloid Leukemia: Response to Tyrosine Kinase Inhibitors and Prognostic Implications

The majority of patients with chronic-phase (CP) chronic myeloid leukemia (CML) who are treated with Bcr-Abl tyrosine kinase inhibitors such as imatinib and dasatinib achieve cytogenetic disease remission (ie, Philadelphia chromosome-positive cells undetectable by cytogenetic evaluation). However, m...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Jabbour, Elias, Cortes, Jorge E., Kantarjian, Hagop M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2008
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5141579/
https://ncbi.nlm.nih.gov/pubmed/18348294
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.23427
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!